Alternative drug discovery approaches for orphan GPCRs

Drug Discovery Today

Volumn 13, Issue 1-2, 2008, Pages 52-58

  Levoye, Angélique ^a,b   Jockers, Ralf ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR;

BINDING SITE; CHEMICAL INTERACTION; DRUG DESIGN; DRUG RESEARCH; LIGAND BINDING; MOLECULAR CLONING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

DRUG DESIGN; DRUG INDUSTRY; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TECHNOLOGY, PHARMACEUTICAL;

EID: 37649013428     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.09.011     Document Type: Review

References (67)

1. Civelli O. GPCR deorphanizations: the novel, the known and the unexpected transmitters. Trends Pharmacol. Sci. 26 (2005) 15-19
2. Civelli O., et al. Novel neurotransmitters as natural ligands of orphan G-protein-coupled receptors. Trends Neurosci. 24 (2001) 230-237
3. Reinscheid R.K., et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270 (1995) 792-794
4. Civelli O., et al. Reverse physiology: discovery of the novel neuropeptide, orphanin FQ/nociceptin. Crit. Rev. Neurobiol. 12 (1998) 163-176
5. Hinuma S., et al. A prolactin-releasing peptide in the brain. Nature 393 (1998) 272-276
6. Kojima M., et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
7. Fergusson S.S., and Caron M.G. Green fluorescent protein-tagged beta-arrestin translocation as a measure of G protein-coupled receptor activation. Methods Mol. Biol. 237 (2004) 121-126
8. Oakley R.H., et al. The ligand-independent translocation assay: an enabling technology for screening orphan G protein-coupled receptors by arrestin recruitment. Methods Enzymol. 414 (2006) 50-63
9. Adie E.J., et al. CypHer 5: a generic approach for measuring the activation and trafficking of G protein-coupled receptors in live cells. Assay Drug Dev. Technol. 1 (2003) 251-259
10. Tunaru S., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9 (2003) 352-355
11. Wise A., et al. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278 (2003) 9869-9874
12. Mendive F., et al. Defective postnatal development of the male reproductive tract in LGR4 knockout mice. Dev. Biol. 290 (2006) 421-434
13. Morita H., et al. Neonatal lethality of LGR5 null mice is associated with ankyloglossia and gastrointestinal distension. Mol. Cell. Biol. 24 (2004) 9736-9743
14. Lefkowitz R.J., and Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 308 (2005) 512-517
15. Cain S.A., and Monk P.N. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J. Biol. Chem. 277 (2002) 7165-7169
16. Kalant D., et al. The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J. Biol. Chem. 278 (2003) 11123-11129
17. Chen N.J., et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 446 (2007) 203-207
18. Mantovani A., et al. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 22 (2001) 328-336
19. McLatchie L.M., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 (1998) 333-339
20. Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci. 2 (2001) 274-286
21. Milligan G. G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discov. Today 11 (2006) 541-549
22. Prinster S.C., et al. Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol. Rev. 57 (2005) 289-298
23. White J.H., et al. Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 396 (1998) 679-682
24. Uberti M.A., et al. Heterodimerization with beta2-adrenergic receptors promotes surface expression and functional activity of alpha1D-adrenergic receptors. J. Pharmacol. Exp. Ther. 313 (2005) 16-23
25. Nelson G., et al. Mammalian sweet taste receptors. Cell 106 (2001) 381-390
26. Nelson G., et al. An amino-acid taste receptor. Nature 416 (2002) 199-202
27. Levoye A., et al. Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers. EMBO Rep 7 (2006) 1094-1098
28. Bond R.A., and Ijzerman A.P. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol. Sci. 27 (2006) 92-96
29. Milligan G. Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol. Pharmacol. 64 (2003) 1271-1276
30. Waldhoer M., et al. Murine cytomegalovirus (CMV) M33 and human CMV US28 receptors exhibit similar constitutive signaling activities. J. Virol. 76 (2002) 8161-8168
31. Vischer H.F., et al. HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signaling networks. Trends Pharmacol. Sci. 27 (2006) 56-63
32. Davis D.J., et al. Insulin Inhibits beta-Adrenergic Responses in Fetal Rabbit Lung in Explant Culture. Am. J. Physiol. 263 5 Pt. 1 (1992) L562-L567
33. Rosenkilde M.M., et al. Molecular pharmacological phenotyping of EBI2. An orphan seven-transmembrane receptor with constitutive activity. J. Biol. Chem. 281 (2006) 13199-13208
34. Tanaka S., et al. Neural expression of G protein-coupled receptors GPR3, GPR6, and GPR12 upregulates cyclic AMP levels and promotes neurite outgrowth. J. Biol. Chem. 282 (2007) 10506-10515
35. Ledent C., et al. Premature ovarian aging in mice deficient for Gpr3. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 8922-8926
36. Mehlmann L.M., et al. The Gs-linked receptor GPR3 maintains meiotic arrest in mammalian oocytes. Science 306 (2004) 1947-1950
37. Jones P.G., et al. Tissue distribution and functional analyses of the constitutively active orphan G protein coupled receptors, GPR26 and GPR78. Biochim. Biophys. Acta 1770 (2007) 890-901
38. Stoddart L.A., et al. Uncovering the pharmacology of the G protein-coupled receptor GPR40: high apparent constitutive activity in guanosine 5′-O-(3-[35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. Mol. Pharmacol. 71 (2007) 994-1005
39. Levoye A., et al. The orphan GPR50 receptor specifically inhibits MT(1) melatonin receptor function through heterodimerization. EMBO J. 25 (2006) 3012-3023
40. Kniazeff J., et al. No ligand binding in the GB2 subunit of the GABA(B) receptor is required for activation and allosteric interaction between the subunits. J. Neurosci. 22 (2002) 7352-7361
41. Neuhaus E.M., et al. Odorant receptor heterodimerization in the olfactory system of Drosophila melanogaster. Nat. Neurosci. 8 (2005) 15-17
42. Benton R., et al. Atypical membrane topology and heteromeric function of Drosophila odorant receptors in vivo. PLoS Biol. 4 (2006) e20
43. Xu H., et al. Different functional roles of T1R subunits in the heteromeric taste receptors. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 14258-14263
44. Milasta S., et al. Interactions between the Mas-related receptors MrgD and MrgE alter signalling and trafficking of MrgD. Mol. Pharmacol. 69 (2006) 479-491
45. Marazziti D., et al. GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 9846-9851
46. Riobo N.A., et al. Hedgehog signal transduction: signal integration and cross talk in development and cancer. Cell Cycle 5 (2006) 1612-1615
47. 2+-dependent BK channel signaling complex by binding to beta2 adrenergic receptor. EMBO J. 23 (2004) 2196-2205
48. 2+ channel Cav1.2. Science 293 (2001) 98-101
49. Beedle A.M., et al. Agonist-independent modulation of N-type calcium channels by ORL1 receptors. Nat. Neurosci. 7 (2004) 118-125
50. Lange J.H., and Kruse C.G. Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov. Today 10 (2005) 693-702
51. Nijenhuis W.A., et al. AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol. Endocrinol. 15 (2001) 164-171
52. Adan R.A., and Kas M.J. Inverse agonism gains weight. Trends Pharmacol. Sci. 24 (2003) 315-321
53. Casarosa P., et al. Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G protein-coupled receptor. J. Biol. Chem. 278 (2003) 5172-5178
54. Bresnick J.N., et al. Identification of signal transduction pathways used by orphan g protein-coupled receptors. Assay Drug Dev. Technol. 1 (2003) 239-249
55. Waldhoer M., et al. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimmers. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 9050-9055
56. May L.T., et al. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 1-51
57. Smit M.J., et al. Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 53-87
58. Binet V., et al. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. J. Biol. Chem. 279 (2004) 29085-29091
59. Pin J.P., et al. Allosteric functioning of dimeric class C G-protein-coupled receptors. FEBS J. 272 (2005) 2947-2955
60. Savi P., et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 11069-11074
61. Hay D.L., et al. GPCR modulation by RAMPs. Pharmacol. Ther. 109 (2006) 173-197
62. Mallee J.J., et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J. Biol. Chem. 277 (2002) 14294-14298
63. Salvatore C.A., et al. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochemistry 45 (2006) 1881-1887
64. Grasberger B.L., et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 48 (2005) 909-912
65. McMillan K., et al. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 1506-1511
66. He M.M., et al. Small-molecule inhibition of TNF-alpha. Science 310 (2005) 1022-1025
67. Oh da Y., et al. Cellular and molecular biology of orphan G protein-coupled receptors. Int. Rev. Cytol. 252 (2006) 163-218